Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125620421 | 12562042 | 1 | I | 20160706 | 20160715 | 20160715 | EXP | JP-ACTELION-A-CH2016-139159 | ACTELION | USHIJIMA R, SHIRAISHI S, NAKAGAICHI M, ONODA H, JOHO S, HIRAI T ET AL.. A CASE IN WHICH USE OF EPOPROSTENOL LED TO PULMONARY CONGESTION IN A PATIENT WITH PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE. THE 229TH HOKURIKU REGIONAL MEETING OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE. 2016;N/A:N/A | 87.00 | YR | E | F | Y | 0.00000 | 20160715 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125620421 | 12562042 | 1 | PS | TRACLEER | BOSENTAN | 1 | Oral | UNK | 21290 | TABLET | |||||||||
| 125620421 | 12562042 | 2 | SS | Epoprostenol ACT | EPOPROSTENOL | 1 | Intravenous (not otherwise specified) | 0.6 NG/KG, PER MIN | Y | 22260 | INJECTION | /min | |||||||
| 125620421 | 12562042 | 3 | C | BERAPROST | BERAPROST | 1 | U | 0 | |||||||||||
| 125620421 | 12562042 | 4 | C | OXYGEN. | OXYGEN | 1 | U | 0 | |||||||||||
| 125620421 | 12562042 | 5 | C | TADALAFIL | TADALAFIL | 1 | U | 0 | |||||||||||
| 125620421 | 12562042 | 6 | C | DOBUTAMINE | DOBUTAMINEDOBUTAMINE HYDROCHLORIDE | 1 | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125620421 | 12562042 | 1 | Pulmonary arterial hypertension |
| 125620421 | 12562042 | 2 | Pulmonary arterial hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125620421 | 12562042 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125620421 | 12562042 | Cardiac output decreased | |
| 125620421 | 12562042 | Condition aggravated | |
| 125620421 | 12562042 | Drug effect incomplete | |
| 125620421 | 12562042 | Dyspnoea | |
| 125620421 | 12562042 | Oxygen saturation decreased | |
| 125620421 | 12562042 | Pulmonary arterial hypertension | |
| 125620421 | 12562042 | Pulmonary congestion | |
| 125620421 | 12562042 | Pulmonary veno-occlusive disease |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |